What is the current Human Interleukin-2 (IL-2) market size?

The Human Interleukin-2 (IL-2) market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Human Interleukin-2 (IL-2) market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Human Interleukin-2 (IL-2) market?

Key drivers include rising cancer incidence and growing adoption of immunotherapy treatments, driving future outlook.

What are the major challenges facing the Human Interleukin-2 (IL-2) market?

Challenges include high development costs, stringent regulations, and intense competition among market players.

Which regions are expected to lead the Human Interleukin-2 (IL-2) market?

North America and Europe are expected to dominate the market, driven by strong healthcare infrastructure.

Who are the top companies in the Human Interleukin-2 (IL-2) market?

Leading companies include Pfizer, Novartis, and Roche, which are investing heavily in research and development.

What future opportunities exist in the Human Interleukin-2 (IL-2) market?

Emerging opportunities include the development of novel immunotherapies and increasing adoption in emerging markets.

How is technology impacting the Human Interleukin-2 (IL-2) market?

Advances in biotechnology and gene editing are enabling the development of more effective and targeted IL-2 therapies.

What is the current regulatory landscape for the Human Interleukin-2 (IL-2) market?

The regulatory landscape is characterized by strict guidelines and oversight from agencies such as the FDA and EMA.

What is the expected future outlook for the Human Interleukin-2 (IL-2) market?

The future outlook is positive, with growing demand and emerging opportunities driving market growth and expansion.

Human Interleukin-2 (IL-2) Market Potential & Strategic Outlook 2033

Human Interleukin-2 (IL-2) by Application (Recombinant Interferon, Recombinant Interleukin, Natural Biological Products, Poison Immune, Gene Therapy, Monoclonal Antibody), by Types (50000 U, 100000 U, 200000 U, 500000 U, 1 Million U, 2 Million U), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Human Interleukin-2 (IL-2) Market Size | CAGR 7.5 Forecast 2033

Human Interleukin-2 (IL-2) Market Potential & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Human Interleukin-2 (IL-2) Market Overview

The Human Interleukin-2 (IL-2) market refers to the industry involved in the research, development, and distribution of IL-2, a type of cytokine that plays a crucial role in the immune system. As the Human Interleukin-2 (IL-2) market size is estimated to be around $1.4 billion, the growth outlook is promising, with a market forecast indicating a significant expansion in the industry expansion. The scope of this market encompasses various immunotherapy applications, including cancer treatment, infectious diseases, and autoimmune disorders, with key synonyms such as IL-2 therapy, immunotherapy, and biologics.

Loading chart…

The current Human Interleukin-2 (IL-2) market size is estimated to be around $1.4 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of 8.5% during the forecast period from 2026 to 2033. The key drivers of this growth include technology shifts, such as advancements in gene editing and cell therapy, regulations, such as favorable government policies, and consumer behavior, such as increasing awareness about immunotherapy. The largest region in the Human Interleukin-2 (IL-2) market is North America, while the fastest-growing region is Asia-Pacific. The market is expected to be shaped by key forces such as competitive intensity, supply-chain dynamics, and innovation.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; BMS; Schering-Plough; AbbVie Inc; Alkermes Plc; APT Therapeutics; Mabtech Limited; Philogen; Sinopharm; Jiangsu Jinsili Pharmaceutical; Shenyang Sansheng Pharmaceutical; Beijing Shuanglu Pharmaceutical; Shandong Quangang Pharmaceutical; Shanghai Huaxin Biological high-tech; Beijing Yuance Pharmaceutical; Beijing Sihuan Biological Pharmaceutical; Beijing Sanyuan Gene Pharmaceutical; Shenzhen Kexing Biological Engineering; Shanghai Sanwei Biotechnology; Xiamen Tebao Biological Engineering; Chengdu huashen Biotechnology; Shanghai Pharma Group; Guangdong Xinghao Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Human Interleukin-2 (IL-2) market is poised for significant growth, driven by increasing demand for immunotherapies and rising investments in research and development. The market dynamics are influenced by various factors, including technological advancements, regulatory approvals, and shifting consumer preferences.

Growth Drivers2 items

The growing prevalence of cancer and autoimmune diseases is driving the demand for Human Interleukin-2 (IL-2) market, with the global market size expected to reach $1.2 billion by 2025, at a growth forecast of 8.5% CAGR.

Advances in biotechnology and gene editing technologies, such as CRISPR, are enabling the development of more effective and targeted IL-2 therapies, further fueling the market growth.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the Human Interleukin-2 (IL-2) market, thereby restricting the market growth.

The IL-2 market is also facing challenges due to the high cost of existing therapies, making them inaccessible to a large patient population, especially in developing economies.

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies is creating new opportunities for the Human Interleukin-2 (IL-2) market, with companies investing heavily in research and development to develop more effective and personalized IL-2 therapies.

The growing demand for immunotherapies in emerging economies is also presenting opportunities for market players to expand their presence and increase their market share in the global Human Interleukin-2 (IL-2) market size.

Challenges2 items

The Human Interleukin-2 (IL-2) market is facing challenges due to the intense competition among existing players, with many companies offering similar products and therapies, making it difficult for new players to enter the market and gain traction.

The IL-2 market is also facing challenges due to the rapid evolution of technologies and therapies, requiring companies to continuously invest in research and development to stay ahead of the competition and meet the changing consumer needs, ultimately impacting the growth forecast.

Market Segmentation

Loading chart…

The Human Interleukin-2 (IL-2) market can be segmented based on application, which plays a crucial role in determining the overall market size. The application segment includes various therapeutic areas where IL-2 is used, such as cancer treatment, immunodeficiency diseases, and infectious diseases. Understanding the Human Interleukin-2 (IL-2) segmentation by application is essential to identify the most significant revenue-generating areas and to develop targeted marketing strategies.

Another critical segmentation category in the Human Interleukin-2 (IL-2) market is types, which includes subtypes such as recombinant IL-2 and natural IL-2. Recombinant IL-2 is the most widely used type, accounting for a significant share of the market. The types segment helps in understanding the different forms of IL-2 available in the market and their respective market shares, enabling companies to focus on the most promising areas for growth and development.

Human Interleukin-2 (IL-2) Segmentation Breakdown14 items

Application

Recombinant Interferon

Recombinant Interleukin

Natural Biological Products

Poison Immune

Gene Therapy

Monoclonal Antibody

Types

50000 U

100000 U

200000 U

500000 U

1 Million U

2 Million U

Regional Insights

Loading chart…

The Human Interleukin-2 (IL-2) market growth is anticipated to vary across regions, with North America emerging as the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of IL-2 therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America - established ecosystem maturity, high demographics awareness, and ongoing research investments; Europe - regulatory support, growing demand for IL-2 therapies, and increasing competition among market players; Asia Pacific - expanding patient population, rising healthcare expenditure, and improving infrastructure; Latin America - government initiatives, increasing access to IL-2 therapies, and growing awareness; and Middle East & Africa - emerging markets, rising demand for innovative therapies, and growing partnerships among market players.

The regional forecast indicates a promising outlook for the Human Interleukin-2 (IL-2) market, with each region presenting unique opportunities and challenges. Understanding these regional dynamics is crucial for market players to develop effective strategies and capitalize on the growing demand for IL-2 therapies.

Competitive Landscape

The Human Interleukin-2 (IL-2) competitive landscape is moderately consolidated, with a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by companies seeking to differentiate themselves through innovative products and strategic partnerships, amidst a backdrop of high competition and margin pressure. Understanding the Human Interleukin-2 (IL-2) key players is crucial for navigating this complex landscape.

Companies in this space employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Technology, service model, channel strength, customization, and cost advantages are key areas of competitive differentiation. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must focus on strategic initiatives that drive growth and innovation.

Roche: regional expansion

BMS: innovation pipeline

Schering-Plough: vertical integration

AbbVie Inc: premium pricing

Alkermes Plc: local manufacturing

APT Therapeutics: OEM tie-ups

Key Human Interleukin-2 (IL-2) Companies23 items

Roche

BMS

Schering-Plough

AbbVie Inc

Alkermes Plc

APT Therapeutics

Mabtech Limited

Philogen

Sinopharm

Jiangsu Jinsili Pharmaceutical

Shenyang Sansheng Pharmaceutical

Beijing Shuanglu Pharmaceutical

Shandong Quangang Pharmaceutical

Shanghai Huaxin Biological high-tech

Beijing Yuance Pharmaceutical

Beijing Sihuan Biological Pharmaceutical

Beijing Sanyuan Gene Pharmaceutical

Shenzhen Kexing Biological Engineering

Shanghai Sanwei Biotechnology

Xiamen Tebao Biological Engineering

Chengdu huashen Biotechnology

Shanghai Pharma Group

Guangdong Xinghao Pharmaceutical

Market Ecosystem

The Human Interleukin-2 (IL-2) ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of IL-2 products, with technology providers and suppliers playing a crucial role in the upstream segment. The midstream segment involves system integrators and manufacturers, while the downstream segment comprises distributors, channel partners, and end users.

Raw material suppliers — providing biochemical components

OEMs/manufacturers — producing IL-2 products

Technology providers — developing IL-2 technologies

System integrators — integrating IL-2 products into treatments

Distributors/channel partners — delivering IL-2 products to end users

Regulators/standards bodies — establishing IL-2 product standards

End users/buyers — utilizing IL-2 products for therapeutic purposes

Within the Human Interleukin-2 (IL-2) ecosystem, control points reside with regulators and standards bodies, as they influence adoption through approvals and standards. Dependency risks arise from input constraints, such as the availability of raw materials, and standards compliance. Switching costs and partnerships also play a role, as end users may face difficulties in transitioning between different IL-2 products or technologies. Furthermore, the ecosystem may differ by region due to varying regulatory requirements and market conditions, emphasizing the need for a thorough value chain analysis to navigate these complexities.

Recent Industry Insights

The Human Interleukin-2 (IL-2) industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships have been forged to enhance research and development of IL-2 based therapies, with a focus on improving treatment outcomes for patients. Notable mergers and acquisitions have also taken place, leading to the expansion of product portfolios and strengthening of market positions.

Furthermore, there have been several product and technology launches, aimed at leveraging the potential of IL-2 in various therapeutic areas. Regulatory changes have also been observed, with updates to guidelines and policies governing the development and approval of IL-2 based treatments. Additionally, funding rounds and expansions have been announced, providing a boost to the growth of the Human Interleukin-2 (IL-2) industry trends.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Human Interleukin-2 (IL-2) market outlook. The market attractiveness is moderate, driven by the growing demand for immunotherapies. The competitive intensity is high, with several key players investing in research and development. The long-term outlook is positive, with potential applications in cancer treatment and autoimmune diseases.

The innovation landscape is dynamic, with ongoing research into new IL-2 therapies. The demand-supply balance is expected to be stable, with increasing demand met by expanding production capacities. Key risk factors include regulatory challenges and potential side effects. Overall, the Human Interleukin-2 (IL-2) market is poised for growth, driven by its potential in immunotherapy and increasing investment in research and development.

11 items

1. Executive Summary

2. Human Interleukin-2 (IL-2) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human Interleukin-2 (IL-2) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Human Interleukin-2 (IL-2) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Recombinant Interferon

6.1.2. Recombinant Interleukin

6.1.3. Natural Biological Products

6.1.4. Poison Immune

6.1.5. Gene Therapy

6.1.6. Monoclonal Antibody

6.2. Global Human Interleukin-2 (IL-2) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 50000 U

6.2.2. 100000 U

6.2.3. 200000 U

6.2.4. 500000 U

6.2.5. 1 Million U

6.2.6. 2 Million U

6.3. Global Human Interleukin-2 (IL-2) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Human Interleukin-2 (IL-2) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human Interleukin-2 (IL-2) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human Interleukin-2 (IL-2) Market Competition by Key Manufacturers

8.1. Global Human Interleukin-2 (IL-2) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Human Interleukin-2 (IL-2): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BMS

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Schering-Plough

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AbbVie Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alkermes Plc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. APT Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Mabtech Limited

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Philogen

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sinopharm

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Jiangsu Jinsili Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Shenyang Sansheng Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Beijing Shuanglu Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shandong Quangang Pharmaceutical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Shanghai Huaxin Biological high-tech

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Beijing Yuance Pharmaceutical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Beijing Sihuan Biological Pharmaceutical

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Beijing Sanyuan Gene Pharmaceutical

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Shenzhen Kexing Biological Engineering

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Shanghai Sanwei Biotechnology

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Xiamen Tebao Biological Engineering

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Chengdu huashen Biotechnology

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Shanghai Pharma Group

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Guangdong Xinghao Pharmaceutical

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human Interleukin-2 (IL-2) Market

Figure 4: Global Human Interleukin-2 (IL-2) Market: Drivers

Figure 5: Global Human Interleukin-2 (IL-2) Market: Challenges

Figure 6: Global Human Interleukin-2 (IL-2) Market: Trends

Figure 7: Global Human Interleukin-2 (IL-2) Market: Opportunity

Figure 8: Global Human Interleukin-2 (IL-2) Market: Restraint

Figure 9: Global Human Interleukin-2 (IL-2) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Human Interleukin-2 (IL-2) Market Value (USD Million) By Region

Figure 15: Global Human Interleukin-2 (IL-2) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Human Interleukin-2 (IL-2) Market Value (USD Million) By Region

Figure 23: Global Human Interleukin-2 (IL-2) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Human Interleukin-2 (IL-2) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human Interleukin-2 (IL-2) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human Interleukin-2 (IL-2) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Human Interleukin-2 (IL-2) Market Value (USD Million) By Region

Table 10: Global Human Interleukin-2 (IL-2) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Human Interleukin-2 (IL-2) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Human Interleukin-2 (IL-2) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Human Interleukin-2 (IL-2) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: BMS Basic Information And Sales Area

Table 33: BMS. Products Portfolio

Table 34: Schering-Plough Basic Information And Sales Area

Table 35: Schering-Plough. Products Portfolio

Table 36: AbbVie Inc Basic Information And Sales Area

Table 37: AbbVie Inc. Products Portfolio

Table 38: Alkermes Plc Basic Information And Sales Area

Table 39: Alkermes Plc. Products Portfolio

Table 40: APT Therapeutics Basic Information And Sales Area

Table 41: APT Therapeutics. Products Portfolio

Table 42: Mabtech Limited Basic Information And Sales Area

Table 43: Mabtech Limited. Products Portfolio

Table 44: Philogen Basic Information And Sales Area

Table 45: Philogen. Products Portfolio

Table 46: Sinopharm Basic Information And Sales Area

Table 47: Sinopharm. Products Portfolio

Table 48: Jiangsu Jinsili Pharmaceutical Basic Information And Sales Area

Table 49: Jiangsu Jinsili Pharmaceutical. Products Portfolio

Table 50: Shenyang Sansheng Pharmaceutical Basic Information And Sales Area

Table 51: Shenyang Sansheng Pharmaceutical. Products Portfolio

Table 52: Beijing Shuanglu Pharmaceutical Basic Information And Sales Area

Table 53: Beijing Shuanglu Pharmaceutical. Products Portfolio

Table 54: Shandong Quangang Pharmaceutical Basic Information And Sales Area

Table 55: Shandong Quangang Pharmaceutical. Products Portfolio

Table 56: Shanghai Huaxin Biological high-tech Basic Information And Sales Area

Table 57: Shanghai Huaxin Biological high-tech. Products Portfolio

Table 58: Beijing Yuance Pharmaceutical Basic Information And Sales Area

Table 59: Beijing Yuance Pharmaceutical. Products Portfolio

Table 60: Beijing Sihuan Biological Pharmaceutical Basic Information And Sales Area

Table 61: Beijing Sihuan Biological Pharmaceutical. Products Portfolio

Table 62: Beijing Sanyuan Gene Pharmaceutical Basic Information And Sales Area

Table 63: Beijing Sanyuan Gene Pharmaceutical. Products Portfolio

Table 64: Shenzhen Kexing Biological Engineering Basic Information And Sales Area

Table 65: Shenzhen Kexing Biological Engineering. Products Portfolio

Table 66: Shanghai Sanwei Biotechnology Basic Information And Sales Area

Table 67: Shanghai Sanwei Biotechnology. Products Portfolio

Table 68: Xiamen Tebao Biological Engineering Basic Information And Sales Area

Table 69: Xiamen Tebao Biological Engineering. Products Portfolio

Table 70: Chengdu huashen Biotechnology Basic Information And Sales Area

Table 71: Chengdu huashen Biotechnology. Products Portfolio

Table 72: Shanghai Pharma Group Basic Information And Sales Area

Table 73: Shanghai Pharma Group. Products Portfolio

Table 74: Guangdong Xinghao Pharmaceutical Basic Information And Sales Area

Table 75: Guangdong Xinghao Pharmaceutical. Products Portfolio

Table 76: Global Market Value (USD Million) (2025-2032) By Application

Table 77: Global Market Share (%) By Application (2032)

Table 78: Global Market Value (USD Million) (2025-2032) By Types

Table 79: Global Market Share (%) By Types (2032)

Table 80: Global Human Interleukin-2 (IL-2) Market Value (USD Million) By Region

Table 81: Global Human Interleukin-2 (IL-2) Market Share (%) By Region (2025-2032)

Table 82: North America Market Value (USD Million) (2025-2032) By Country

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: North America Market Value (USD Million) (2025-2032) By Types

Table 85: Europe Market Value (USD Million) (2025-2032) By Country

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Europe Market Value (USD Million) (2025-2032) By Types

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 91: South America Market Value (USD Million) (2025-2032) By Country

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: South America Market Value (USD Million) (2025-2032) By Types

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Human Interleukin-2 (IL-2) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; BMS; Schering-Plough; AbbVie Inc; Alkermes Plc; APT Therapeutics; Mabtech Limited; Philogen; Sinopharm; Jiangsu Jinsili Pharmaceutical; Shenyang Sansheng Pharmaceutical; Beijing Shuanglu Pharmaceutical; Shandong Quangang Pharmaceutical; Shanghai Huaxin Biological high-tech; Beijing Yuance Pharmaceutical; Beijing Sihuan Biological Pharmaceutical; Beijing Sanyuan Gene Pharmaceutical; Shenzhen Kexing Biological Engineering; Shanghai Sanwei Biotechnology; Xiamen Tebao Biological Engineering; Chengdu huashen Biotechnology; Shanghai Pharma Group; Guangdong Xinghao Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options